Art. -Nr.: HY-174976

FHND5032

Kundenbewertung

Based on 1 Customer Validation

FHND5032 is an orally active miR-124 inducer. FHND5032 significantly upregulates miR-124 expression in macrophages. FHND5032 disrupts inflammatory signaling, promotes macrophage reprogramming, and restores the epithelial barrier function by inhibiting the PIK3R2/PI3K/Akt axis. FHND5032 alleviates colitis and reduces inflammatory burden in ulcerative colitis mice. FHND5032 can be used for the study of ulcerative colitis.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.49%
CAS. Nr.: 3076057-63-8
Formel: C₁₅H₉ClF₃N₃O
Molecular Weight:339.70

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

FHND5032 Chemical Structure

CAS. Nr.: 3076057-63-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle PI3K Isoform-spezifische Produkte anzeigen :

Alle Akt Isoform-spezifische Produkte anzeigen :

Alle Interleukin Related Isoform-spezifische Produkte anzeigen :

In Vitro

FHND5032 (0-20 μM, 24 h) significantly exerts anti-inflammatory activity in THP-1 and RAW 264.7 cells by enhancing miR-124 expression^[1].
FHND5032 (≤ 5 μM) activates miR-124-5p expression to regulate the PI3K/Akt pathway by targeting PIK3R2 in THP-1 and RAW 264.7 cells reprogramming^[1].
FHND5032 decreases the expression of M1 marker CD86 while increasing the expression of M2 marker CD206 in RAW 264.7 cells^[1].
FHND5032 promots the expression of the barrier-sealing proteins ZO-1 and occludin to facilitate Tight junction (TJ) assembly in Caco-2 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Real Time qPCR^[1]

Cell Line:

THP-1 and RAW 264.7 cells
Concentration:

5, 10 μM
Incubation Time:

/
Result:

Upregulated miR-124 levels and induced miR-124 expression, which peaked at a concentration of 5 μM.
Decreased TNF-α, IL-1β, and IL-6 expression in LPS (HY-D1056)- and IFN-γ-stimulated THP-1 cells and LPS stimulated RAW 264.7 cells.
Decreased the expression of PIK3R2

In Vivo

FHND5032 (25-50 mg/kg, i.g., daily, 12 days) alleviates colitis and reduces inflammatory burden in Dextran sulfate sodium salt (DSS) (HY-116282C)-induced ulcerative colitis (UC) mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

DSS-induced female C57BL/6J mice (18-20 g)^[1]
Dosage:

25, 50 mg/kg
Administration:

i.g. once daily for 12 days
Result:

Restrained the body weight loss of DSS-induced colitis mice.
Reduced the hematochezia occurrence during treatment.
Showed longer colon length of mice.
Protected the colonic barrier from pathological damage.
Decreased the local level of UC-associated myeloperoxidase (MPO) in the colon.
Reduced the expression of pro-inflammatory cytokines, including IL-6, TNF-α, and IFN-γ.
Increased the expression of anti-inflammatory cytokines IL-10.
Prevented intestinal damage in UC through elevation of TJ proteins.
Prevented the FITC-dextran leakage.
Inhibited colonic inflammation and repaired the intestinal barrier in colitis mice.
Upregulated the miR-124 expression and decreased PIK3R2 expression.
Attenuated PIK3R2 upregulation and the hyperphosphorylation of PI3K and Akt.
Showed no significant discrepancies in serum physicochemical parameters (alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), and creatinine (Cr)).
Decreased the abundance of Proteobacteria in colitis mice and effectively enhanced the relative abundance of Firmicutes.
Showed no increase on the abundance of Bacteroidota.

Chemical Information

CAS. Nr. 3076057-63-8
Appearance Solid
Molecular Weight 339.70
Formel C₁₅H₉ClF₃N₃O
Color Light yellow to yellow
SMILES

FC(F)(OC1=CC=C(C=C1)NC2=NC3=CC(Cl)=CC=C3C=N2)F
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (147.19 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.9438 mL

14.7189 mL

29.4377 mL

5 mM

0.5888 mL

2.9438 mL

5.8875 mL

10 mM

0.2944 mL

1.4719 mL

2.9438 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Wang T, et al. Novel Small-Molecule miR-124 Inducer Acts as "a Physiological Brake" of Inflammation in Ulcerative Colitis by Targeting the PIK3R2/PI3K/Akt Axis. J Med Chem. 2025 Jul 10;68(13):14114-14126. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.9438 mL	14.7189 mL	29.4377 mL	73.5943 mL
	5 mM	0.5888 mL	2.9438 mL	5.8875 mL	14.7189 mL
	10 mM	0.2944 mL	1.4719 mL	2.9438 mL	7.3594 mL
	15 mM	0.1963 mL	0.9813 mL	1.9625 mL	4.9063 mL
	20 mM	0.1472 mL	0.7359 mL	1.4719 mL	3.6797 mL
	25 mM	0.1178 mL	0.5888 mL	1.1775 mL	2.9438 mL
	30 mM	0.0981 mL	0.4906 mL	0.9813 mL	2.4531 mL
	40 mM	0.0736 mL	0.3680 mL	0.7359 mL	1.8399 mL
	50 mM	0.0589 mL	0.2944 mL	0.5888 mL	1.4719 mL
	60 mM	0.0491 mL	0.2453 mL	0.4906 mL	1.2266 mL
	80 mM	0.0368 mL	0.1840 mL	0.3680 mL	0.9199 mL
	100 mM	0.0294 mL	0.1472 mL	0.2944 mL	0.7359 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

FHND5032

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Antibacterial Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Cytokine Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Macrophage Related Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Lactylation Compound Library

Alle PI3K Isoform-spezifische Produkte anzeigen

Alle Akt Isoform-spezifische Produkte anzeigen

Alle Interleukin Related Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

FHND5032 Related Classifications

HY-174976 Related Classifications